The DOI matches its Crossref record.
Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease
Open accessAbstract
Purpose: Patients with chronic lymphocytic leukemia (CLL) with high-risk genomic features achieve poor outcomes with traditional therapies. A phase I study of a pharmacokinetically derived schedule of flavopiridol suggested promising activity in CLL, irrespective of high-risk features. Given the relevance of these findings to treating genetically high-risk CLL, a prospective confirmatory study was initiated. Patients and Methods: Patients with relapsed CLL were treated with single-agent flavopiridol, with subsequent addition of dexamethasone to suppress cytokine release syndrome (CRS). High-risk genomic features were prospectively assessed for response to therapy. Results: Sixty-four patients were enrolled. Median age was 60 years, median number of prior therapies was four, and all patients had received prior purine analog therapy. If patients tolerated treatment during week 1, dose escalation occurred during week 2. Dose escalation did not occur in four patients, as a result of severe tumor lysis syndrome; three of these patients required hemodialysis. Thirty-four patients (53%) achieved response, including 30 partial responses (PRs; 47%), three nodular PRs (5%), and one complete response (1.6%). A majority of high-risk patients responded; 12 (57%) of 21 patients with del(17p13.1) and 14 (50%) of 28 patients with del(11q22.3) responded irrespective of lymph node size. Median progression-free survival among responders was 10 to 12 months across all cytogenetic risk groups. Reducing the number of weekly treatments per cycle from four to three and adding prophylactic dexamethasone, which abrogated interleukin-6 release and CRS (P ≤ .01), resulted in improved tolerability and treatment delivery. Conclusion: Flavopiridol achieves significant clinical activity in patients with relapsed CLL, including those with high-risk genomic features and bulky lymphadenopathy. Subsequent clinical trials should use the amended treatment schedule developed herein and prophylactic corticosteroids.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
Broad targeting of resistance to apoptosis in cancer
Mohammad, R. M., Muqbil, I., Lowe, L., Yedjou, C., Hsu, H.-Y., Lin, L.-T., Siegelin, M. D., Fimognari, C., Kumar, N. B., Dou, Q. P., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.001 · Cited by 864
Ding, L., Cao, J., Lin, W., Chen, H., Xiong, X., Ao, H., Yu, M., Lin, J., & Cui, Q. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061960 · Cited by 618
Flavonoids as prospective compounds for anti-cancer therapy
Ravishankar, D., Rajora, A. K., Greco, F., & Osborn, H. M. I. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.10.004 · Cited by 572
Böttcher, S., Ritgen, M., Fischer, K., Stilgenbauer, S., Busch, R. M., Fingerle-Rowson, G., Fink, A. M., Bühler, A., Zenz, T., Wenger, M. K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.9348 · Cited by 460
RETRACTED: Therapeutic potential of flavonoids in cancer: ROS-mediated mechanisms
Slika, H., Mansour, H., Wehbe, N., Nasser, S. A., Iratni, R., Nasrallah, G., Shaito, A., Ghaddar, T., Kobeissy, F., & Eid, A. H. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112442 · Cited by 441
RetractedMantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era
Pérez-Galán, P., Dreyling, M., & Wiestner, A. (2011) · Blood · doi:10.1182/blood-2010-04-189977 · Cited by 394
Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.035 · Cited by 393
Rossi, D., Spina, V., Deambrogi, C., Rasi, S., Laurenti, L., Stamatopoulos, K., Arcaini, L., Lucioni, M., Rocque, G. B., Xu-Monette, Z. Y., et al. (2011) · Blood · doi:10.1182/blood-2010-09-302174 · Cited by 386
Farooqui, M. Z. H., Valdez, J., Martyr, S., Aue, G., Saba, N., Niemann, C. U., Herman, S. E. M., Tian, X., Marti, G., Soto, S., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71182-9 · Cited by 372
Self-citationTargeting cell cycle regulation in cancer therapy
Diaz-Moralli, S., Tarrado-Castellarnau, M., Miranda, A., & Cascante, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.011 · Cited by 361
Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors
Peyressatre, M., Prével, C., Pellerano, M., & Morris, M. (2015) · Cancers · doi:10.3390/cancers7010179 · Cited by 344
The Molecular Balancing Act of p16INK4a in Cancer and Aging
LaPak, K. M., & Burd, C. E. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0350 · Cited by 291
Schwartz, G. K., LoRusso, P. M., Dickson, M. A., Randolph, S. S., Shaik, M. N., Wilner, K. D., Courtney, R., & O'Dwyer, P. J. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.177 · Cited by 260
Luke, J. J., D'Adamo, D. R., Dickson, M. A., Keohan, M. L., Carvajal, R. D., Maki, R. G., de Stanchina, E., Musi, E., Singer, S., & Schwartz, G. K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3203 · Cited by 95
El-Khoury, V, Pierson, S., Szwarcbart, E., Brons, N. H. C., Roland, O., Cherrier-De Wilde, S., Plawny, L., Van Dyck, E., & Berchem, G. (2014) · Leukemia · doi:10.1038/leu.2014.19 · Cited by 73
Metadata
- Authors
- Lin, T. S., Ruppert, A. S., Johnson, A. J., Fischer, B., Heerema, N. A., Andritsos, L. A., Blum, K. A., Flynn, J. M., Jones, J. A., Hu, W., Moran, M. E., Mitchell, S. M., Smith, L. L., Wagner, A. J., Raymond, C. A., Schaaf, L. J., Phelps, M. A., Villalona-Calero, M. A., Grever, M. R., & Byrd, J. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-12-10
- Volume
- 27
- Issue
- 35
- Pages
- 6012-6018
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2139793858
- Cited by
- 222
- References
- 0
- FWCI
- 14.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.